APO Research
Talk to an analyst

APO RESEARCH · REPORT

Radionuclide Drug Conjugate(RDC)

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Radionuclide Drug Conjugate(RDC) Market Analysis and Forecast 2026-2032

29 December 2025197 pages

Choose your research edition.

Industry ResearchRadionuclide Drug Conjugate(RDC) Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Radionuclide Drug Conjugate(RDC) Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Radionuclide Drug Conjugate(RDC) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Radionuclide Drug Conjugate(RDC) Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Radionuclide Drug Conjugate(RDC) Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Radionuclide Drug Conjugate(RDC) market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Radionuclide Drug Conjugate(RDC) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Radionuclide Drug Conjugate(RDC) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Radionuclide Drug Conjugate(RDC) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Radionuclide Drug Conjugate(RDC) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Radionuclide Drug Conjugate(RDC) include China Tongfang Pharmaceuticals, Zhihe Biotechnology, Yuanda Pharmaceuticals, Novartis, Kelun Biotech, Hengrui, Fulian Pharmaceuticals, Dongcheng Pharmaceuticals and Bayer, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Radionuclide Drug Conjugate(RDC), market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Radionuclide Drug Conjugate(RDC), also provides the revenue of main regions and countries. Of the upcoming market potential for Radionuclide Drug Conjugate(RDC), and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Radionuclide Drug Conjugate(RDC) revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Radionuclide Drug Conjugate(RDC) market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Radionuclide Drug Conjugate(RDC) revenue, projected growth trends, production technology, application and end-user industry.

Radionuclide Drug Conjugate(RDC) Segment by Company

China Tongfang Pharmaceuticals

Zhihe Biotechnology

Yuanda Pharmaceuticals

Novartis

Kelun Biotech

Hengrui

Fulian Pharmaceuticals

Dongcheng Pharmaceuticals

Bayer

Telix Pharmaceuticals

Lantheus

Curium

Radionuclide Drug Conjugate(RDC) Segment by Type

Therapy

Diagnosis

Radionuclide Drug Conjugate(RDC) Segment by Application

Prostate Cancer

Neuroendocrine Cancer

Other

Radionuclide Drug Conjugate(RDC) Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Radionuclide Drug Conjugate(RDC) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Radionuclide Drug Conjugate(RDC) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Radionuclide Drug Conjugate(RDC).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Radionuclide Drug Conjugate(RDC) in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Radionuclide Drug Conjugate(RDC) company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Radionuclide Drug Conjugate(RDC) revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Radionuclide Drug Conjugate(RDC) Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Therapy Major Player Table 3. Diagnosis Major Player Table 4. Global Radionuclide Drug Conjugate(RDC) Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Prostate Cancer Major Player Table 6. Neuroendocrine Cancer Major Player Table 7. Other Major Player Table 8. Radionuclide Drug Conjugate(RDC) Industry Trends Table 9. Radionuclide Drug Conjugate(RDC) Industry Drivers Table 10. Radionuclide Drug Conjugate(RDC) Industry Opportunities and Challenges Table 11. Radionuclide Drug Conjugate(RDC) Industry Restraints Table 12. Global Radionuclide Drug Conjugate(RDC) Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 13. Global Radionuclide Drug Conjugate(RDC) Market Size by Region (2021-2026) & (US$ Million) Table 14. Global Radionuclide Drug Conjugate(RDC) Market Share by Region (2021-2026) Table 15. Global Radionuclide Drug Conjugate(RDC) Market Size by Region (2027-2032) & (US$ Million) Table 16. Global Radionuclide Drug Conjugate(RDC) Market Share by Region (2027-2032) Table 17. Global Radionuclide Drug Conjugate(RDC) Revenue by Players (US$ Million) & (2021-2026) Table 18. Global Radionuclide Drug Conjugate(RDC) Revenue Market Share by Players (2021-2026) Table 19. Global Radionuclide Drug Conjugate(RDC) Key Players Ranking, 2024 VS 2025 VS 2026 Table 20. Global Radionuclide Drug Conjugate(RDC) Key Players Headquarters & Area Served Table 21. Global Radionuclide Drug Conjugate(RDC) Players, Product Type & Application Table 22. Global Radionuclide Drug Conjugate(RDC) Players Establishment Date Table 23. Global Players Market Concentration Ratio (CR5 and HHI) Table 24. Global Radionuclide Drug Conjugate(RDC) by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 25. Global Radionuclide Drug Conjugate(RDC) Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Radionuclide Drug Conjugate(RDC) Revenue by Type (2021-2026) & (US$ Million) Table 27. Global Radionuclide Drug Conjugate(RDC) Revenue by Type (2027-2032) & (US$ Million) Table 28. Global Radionuclide Drug Conjugate(RDC) Revenue Market Share by Type (2021-2026) Table 29. Global Radionuclide Drug Conjugate(RDC) Revenue Market Share by Type (2027-2032) Table 30. Global Radionuclide Drug Conjugate(RDC) Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Radionuclide Drug Conjugate(RDC) Revenue by Application (2021-2026) & (US$ Million) Table 32. Global Radionuclide Drug Conjugate(RDC) Revenue by Application (2027-2032) & (US$ Million) Table 33. Global Radionuclide Drug Conjugate(RDC) Revenue Market Share by Application (2021-2026) Table 34. Global Radionuclide Drug Conjugate(RDC) Revenue Market Share by Application (2027-2032) Table 35. China Tongfang Pharmaceuticals Company Information Table 36. China Tongfang Pharmaceuticals Business Overview Table 37. China Tongfang Pharmaceuticals Radionuclide Drug Conjugate(RDC) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. China Tongfang Pharmaceuticals Radionuclide Drug Conjugate(RDC) Product Portfolio Table 39. China Tongfang Pharmaceuticals Recent Development Table 40. Zhihe Biotechnology Company Information Table 41. Zhihe Biotechnology Business Overview Table 42. Zhihe Biotechnology Radionuclide Drug Conjugate(RDC) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Zhihe Biotechnology Radionuclide Drug Conjugate(RDC) Product Portfolio Table 44. Zhihe Biotechnology Recent Development Table 45. Yuanda Pharmaceuticals Company Information Table 46. Yuanda Pharmaceuticals Business Overview Table 47. Yuanda Pharmaceuticals Radionuclide Drug Conjugate(RDC) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Yuanda Pharmaceuticals Radionuclide Drug Conjugate(RDC) Product Portfolio Table 49. Yuanda Pharmaceuticals Recent Development Table 50. Novartis Company Information Table 51. Novartis Business Overview Table 52. Novartis Radionuclide Drug Conjugate(RDC) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Novartis Radionuclide Drug Conjugate(RDC) Product Portfolio Table 54. Novartis Recent Development Table 55. Kelun Biotech Company Information Table 56. Kelun Biotech Business Overview Table 57. Kelun Biotech Radionuclide Drug Conjugate(RDC) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. Kelun Biotech Radionuclide Drug Conjugate(RDC) Product Portfolio Table 59. Kelun Biotech Recent Development Table 60. Hengrui Company Information Table 61. Hengrui Business Overview Table 62. Hengrui Radionuclide Drug Conjugate(RDC) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. Hengrui Radionuclide Drug Conjugate(RDC) Product Portfolio Table 64. Hengrui Recent Development Table 65. Fulian Pharmaceuticals Company Information Table 66. Fulian Pharmaceuticals Business Overview Table 67. Fulian Pharmaceuticals Radionuclide Drug Conjugate(RDC) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. Fulian Pharmaceuticals Radionuclide Drug Conjugate(RDC) Product Portfolio Table 69. Fulian Pharmaceuticals Recent Development Table 70. Dongcheng Pharmaceuticals Company Information Table 71. Dongcheng Pharmaceuticals Business Overview Table 72. Dongcheng Pharmaceuticals Radionuclide Drug Conjugate(RDC) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. Dongcheng Pharmaceuticals Radionuclide Drug Conjugate(RDC) Product Portfolio Table 74. Dongcheng Pharmaceuticals Recent Development Table 75. Bayer Company Information Table 76. Bayer Business Overview Table 77. Bayer Radionuclide Drug Conjugate(RDC) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 78. Bayer Radionuclide Drug Conjugate(RDC) Product Portfolio Table 79. Bayer Recent Development Table 80. Telix Pharmaceuticals Company Information Table 81. Telix Pharmaceuticals Business Overview Table 82. Telix Pharmaceuticals Radionuclide Drug Conjugate(RDC) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 83. Telix Pharmaceuticals Radionuclide Drug Conjugate(RDC) Product Portfolio Table 84. Telix Pharmaceuticals Recent Development Table 85. Lantheus Company Information Table 86. Lantheus Business Overview Table 87. Lantheus Radionuclide Drug Conjugate(RDC) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. Lantheus Radionuclide Drug Conjugate(RDC) Product Portfolio Table 89. Lantheus Recent Development Table 90. Curium Company Information Table 91. Curium Business Overview Table 92. Curium Radionuclide Drug Conjugate(RDC) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Curium Radionuclide Drug Conjugate(RDC) Product Portfolio Table 94. Curium Recent Development Table 95. North America Radionuclide Drug Conjugate(RDC) Revenue by Type (2021-2026) & (US$ Million) Table 96. North America Radionuclide Drug Conjugate(RDC) Revenue by Type (2027-2032) & (US$ Million) Table 97. North America Radionuclide Drug Conjugate(RDC) Revenue by Application (2021-2026) & (US$ Million) Table 98. North America Radionuclide Drug Conjugate(RDC) Revenue by Application (2027-2032) & (US$ Million) Table 99. North America Radionuclide Drug Conjugate(RDC) Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 100. North America Radionuclide Drug Conjugate(RDC) Revenue by Country (2021-2026) & (US$ Million) Table 101. North America Radionuclide Drug Conjugate(RDC) Revenue by Country (US$ Million) & (2027-2032) Table 102. Europe Radionuclide Drug Conjugate(RDC) Revenue by Type (2021-2026) & (US$ Million) Table 103. Europe Radionuclide Drug Conjugate(RDC) Revenue by Type (2027-2032) & (US$ Million) Table 104. Europe Radionuclide Drug Conjugate(RDC) Revenue by Application (2021-2026) & (US$ Million) Table 105. Europe Radionuclide Drug Conjugate(RDC) Revenue by Application (2027-2032) & (US$ Million) Table 106. Europe Radionuclide Drug Conjugate(RDC) Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 107. Europe Radionuclide Drug Conjugate(RDC) Revenue by Country (2021-2026) & (US$ Million) Table 108. Europe Radionuclide Drug Conjugate(RDC) Revenue by Country (US$ Million) & (2027-2032) Table 109. China Radionuclide Drug Conjugate(RDC) Revenue by Type (2021-2026) & (US$ Million) Table 110. China Radionuclide Drug Conjugate(RDC) Revenue by Type (2027-2032) & (US$ Million) Table 111. China Radionuclide Drug Conjugate(RDC) Revenue by Application (2021-2026) & (US$ Million) Table 112. China Radionuclide Drug Conjugate(RDC) Revenue by Application (2027-2032) & (US$ Million) Table 113. Asia Radionuclide Drug Conjugate(RDC) Revenue by Type (2021-2026) & (US$ Million) Table 114. Asia Radionuclide Drug Conjugate(RDC) Revenue by Type (2027-2032) & (US$ Million) Table 115. Asia Radionuclide Drug Conjugate(RDC) Revenue by Application (2021-2026) & (US$ Million) Table 116. Asia Radionuclide Drug Conjugate(RDC) Revenue by Application (2027-2032) & (US$ Million) Table 117. Asia Radionuclide Drug Conjugate(RDC) Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 118. Asia Radionuclide Drug Conjugate(RDC) Revenue by Region (US$ Million) & (2021-2026) Table 119. Asia Radionuclide Drug Conjugate(RDC) Revenue by Region (US$ Million) & (2027-2032) Table 120. SAMEA Radionuclide Drug Conjugate(RDC) Revenue by Type (2021-2026) & (US$ Million) Table 121. SAMEA Radionuclide Drug Conjugate(RDC) Revenue by Type (2027-2032) & (US$ Million) Table 122. SAMEA Radionuclide Drug Conjugate(RDC) Revenue by Application (2021-2026) & (US$ Million) Table 123. SAMEA Radionuclide Drug Conjugate(RDC) Revenue by Application (2027-2032) & (US$ Million) Table 124. SAMEA Radionuclide Drug Conjugate(RDC) Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 125. SAMEA Radionuclide Drug Conjugate(RDC) Revenue by Country (2021-2026) & (US$ Million) Table 126. SAMEA Radionuclide Drug Conjugate(RDC) Revenue by Country (US$ Million) & (2027-2032) Table 127. Research Programs/Design for This Report Table 128. Authors List of This Report Table 129. Secondary Sources Table 130. Primary Sources List of Figures Figure 1. Radionuclide Drug Conjugate(RDC) Image Figure 2. Global Radionuclide Drug Conjugate(RDC) Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Radionuclide Drug Conjugate(RDC) Market Size Share 2021 VS 2025 VS 2032 Figure 4. Therapy Image Figure 5. Diagnosis Image Figure 6. Global Radionuclide Drug Conjugate(RDC) Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Radionuclide Drug Conjugate(RDC) Market Size Share 2021 VS 2025 VS 2032 Figure 8. Prostate Cancer Image Figure 9. Neuroendocrine Cancer Image Figure 10. Other Image Figure 11. Global Radionuclide Drug Conjugate(RDC) Market Size (US$ Million) & (2021-2032) Figure 12. Global Radionuclide Drug Conjugate(RDC) Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Radionuclide Drug Conjugate(RDC) Market Share by Region: 2021 VS 2025 VS 2032 Figure 14. Global Radionuclide Drug Conjugate(RDC) Players Revenue Share Top 10 and Top 5 in 2025 Figure 15. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 16. Global Radionuclide Drug Conjugate(RDC) Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Radionuclide Drug Conjugate(RDC) Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Radionuclide Drug Conjugate(RDC) Revenue Market Share by Type (2021-2032) Figure 19. Global Radionuclide Drug Conjugate(RDC) Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Radionuclide Drug Conjugate(RDC) Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 21. Global Radionuclide Drug Conjugate(RDC) Revenue Market Share by Application (2021-2032) Figure 22. North America Radionuclide Drug Conjugate(RDC) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 23. North America Radionuclide Drug Conjugate(RDC) Revenue Share by Type (2021-2032) Figure 24. North America Radionuclide Drug Conjugate(RDC) Revenue Share by Application (2021-2032) Figure 25. North America Radionuclide Drug Conjugate(RDC) Revenue Share by Country (2021-2032) Figure 26. United States Radionuclide Drug Conjugate(RDC) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Canada Radionuclide Drug Conjugate(RDC) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Mexico Radionuclide Drug Conjugate(RDC) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Europe Radionuclide Drug Conjugate(RDC) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 30. Europe Radionuclide Drug Conjugate(RDC) Revenue Share by Type (2021-2032) Figure 31. Europe Radionuclide Drug Conjugate(RDC) Revenue Share by Application (2021-2032) Figure 32. Europe Radionuclide Drug Conjugate(RDC) Revenue Share by Country (2021-2032) Figure 33. Germany Radionuclide Drug Conjugate(RDC) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. France Radionuclide Drug Conjugate(RDC) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. U.K. Radionuclide Drug Conjugate(RDC) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Italy Radionuclide Drug Conjugate(RDC) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Spain Radionuclide Drug Conjugate(RDC) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Russia Radionuclide Drug Conjugate(RDC) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Netherlands Radionuclide Drug Conjugate(RDC) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Nordic Countries Radionuclide Drug Conjugate(RDC) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. China Radionuclide Drug Conjugate(RDC) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 42. China Radionuclide Drug Conjugate(RDC) Revenue Share by Type (2021-2032) Figure 43. China Radionuclide Drug Conjugate(RDC) Revenue Share by Application (2021-2032) Figure 44. Asia Radionuclide Drug Conjugate(RDC) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. Asia Radionuclide Drug Conjugate(RDC) Revenue Share by Type (2021-2032) Figure 46. Asia Radionuclide Drug Conjugate(RDC) Revenue Share by Application (2021-2032) Figure 47. Asia Radionuclide Drug Conjugate(RDC) Revenue Share by Region (2021-2032) Figure 48. Japan Radionuclide Drug Conjugate(RDC) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. South Korea Radionuclide Drug Conjugate(RDC) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. India Radionuclide Drug Conjugate(RDC) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Australia Radionuclide Drug Conjugate(RDC) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Taiwan Radionuclide Drug Conjugate(RDC) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Southeast Asia Radionuclide Drug Conjugate(RDC) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. SAMEA Radionuclide Drug Conjugate(RDC) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 55. SAMEA Radionuclide Drug Conjugate(RDC) Revenue Share by Type (2021-2032) Figure 56. SAMEA Radionuclide Drug Conjugate(RDC) Revenue Share by Application (2021-2032) Figure 57. SAMEA Radionuclide Drug Conjugate(RDC) Revenue Share by Country (2021-2032) Figure 58. Brazil Radionuclide Drug Conjugate(RDC) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Argentina Radionuclide Drug Conjugate(RDC) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Chile Radionuclide Drug Conjugate(RDC) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Colombia Radionuclide Drug Conjugate(RDC) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Peru Radionuclide Drug Conjugate(RDC) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Saudi Arabia Radionuclide Drug Conjugate(RDC) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Israel Radionuclide Drug Conjugate(RDC) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. UAE Radionuclide Drug Conjugate(RDC) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Turkey Radionuclide Drug Conjugate(RDC) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Iran Radionuclide Drug Conjugate(RDC) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Egypt Radionuclide Drug Conjugate(RDC) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Therapy
  • Diagnosis
Applications
  • Prostate Cancer
  • Neuroendocrine Cancer
  • Other
Companies covered
  • China Tongfang Pharmaceuticals
  • Zhihe Biotechnology
  • Yuanda Pharmaceuticals
  • Novartis
  • Kelun Biotech
  • Hengrui
  • Fulian Pharmaceuticals
  • Dongcheng Pharmaceuticals
  • Bayer
  • Telix Pharmaceuticals
  • Lantheus
  • Curium

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Radionuclide Drug Conjugate(RDC) Market by Type
  3. 1.2.1 Global Radionuclide Drug Conjugate(RDC) Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Therapy
  5. 1.2.3 Diagnosis
  6. 1.3 Radionuclide Drug Conjugate(RDC) Market by Application
  7. 1.3.1 Global Radionuclide Drug Conjugate(RDC) Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Prostate Cancer
  9. 1.3.3 Neuroendocrine Cancer
  10. 1.3.4 Other
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Radionuclide Drug Conjugate(RDC) Market Dynamics
  1. 2.1 Radionuclide Drug Conjugate(RDC) Industry Trends
  2. 2.2 Radionuclide Drug Conjugate(RDC) Industry Drivers
  3. 2.3 Radionuclide Drug Conjugate(RDC) Industry Opportunities and Challenges
  4. 2.4 Radionuclide Drug Conjugate(RDC) Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Radionuclide Drug Conjugate(RDC) Market Perspective (2021-2032)
  2. 3.2 Global Radionuclide Drug Conjugate(RDC) Growth Trends by Region
  3. 3.2.1 Global Radionuclide Drug Conjugate(RDC) Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Radionuclide Drug Conjugate(RDC) Market Size by Region (2021-2026)
  5. 3.2.3 Global Radionuclide Drug Conjugate(RDC) Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Radionuclide Drug Conjugate(RDC) Revenue by Players
  2. 4.1.1 Global Radionuclide Drug Conjugate(RDC) Revenue by Players (2021-2026)
  3. 4.1.2 Global Radionuclide Drug Conjugate(RDC) Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Radionuclide Drug Conjugate(RDC) Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Radionuclide Drug Conjugate(RDC) Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Radionuclide Drug Conjugate(RDC) Key Players Headquarters & Area Served
  7. 4.4 Global Radionuclide Drug Conjugate(RDC) Players, Product Type & Application
  8. 4.5 Global Radionuclide Drug Conjugate(RDC) Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Radionuclide Drug Conjugate(RDC) Market CR5 and HHI
  11. 4.6.3 2025 Radionuclide Drug Conjugate(RDC) Tier 1, Tier 2, and Tier 3
5 Radionuclide Drug Conjugate(RDC) Market Size by Type
  1. 5.1 Global Radionuclide Drug Conjugate(RDC) Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Radionuclide Drug Conjugate(RDC) Revenue by Type (2021-2032)
  3. 5.3 Global Radionuclide Drug Conjugate(RDC) Revenue Market Share by Type (2021-2032)
6 Radionuclide Drug Conjugate(RDC) Market Size by Application
  1. 6.1 Global Radionuclide Drug Conjugate(RDC) Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Radionuclide Drug Conjugate(RDC) Revenue by Application (2021-2032)
  3. 6.3 Global Radionuclide Drug Conjugate(RDC) Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 China Tongfang Pharmaceuticals
  2. 7.1.1 China Tongfang Pharmaceuticals Company Information
  3. 7.1.2 China Tongfang Pharmaceuticals Business Overview
  4. 7.1.3 China Tongfang Pharmaceuticals Radionuclide Drug Conjugate(RDC) Revenue and Gross Margin (2021-2026)
  5. 7.1.4 China Tongfang Pharmaceuticals Radionuclide Drug Conjugate(RDC) Product Portfolio
  6. 7.1.5 China Tongfang Pharmaceuticals Recent Developments
  7. 7.2 Zhihe Biotechnology
  8. 7.2.1 Zhihe Biotechnology Company Information
  9. 7.2.2 Zhihe Biotechnology Business Overview
  10. 7.2.3 Zhihe Biotechnology Radionuclide Drug Conjugate(RDC) Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Zhihe Biotechnology Radionuclide Drug Conjugate(RDC) Product Portfolio
  12. 7.2.5 Zhihe Biotechnology Recent Developments
  13. 7.3 Yuanda Pharmaceuticals
  14. 7.3.1 Yuanda Pharmaceuticals Company Information
  15. 7.3.2 Yuanda Pharmaceuticals Business Overview
  16. 7.3.3 Yuanda Pharmaceuticals Radionuclide Drug Conjugate(RDC) Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Yuanda Pharmaceuticals Radionuclide Drug Conjugate(RDC) Product Portfolio
  18. 7.3.5 Yuanda Pharmaceuticals Recent Developments
  19. 7.4 Novartis
  20. 7.4.1 Novartis Company Information
  21. 7.4.2 Novartis Business Overview
  22. 7.4.3 Novartis Radionuclide Drug Conjugate(RDC) Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Novartis Radionuclide Drug Conjugate(RDC) Product Portfolio
  24. 7.4.5 Novartis Recent Developments
  25. 7.5 Kelun Biotech
  26. 7.5.1 Kelun Biotech Company Information
  27. 7.5.2 Kelun Biotech Business Overview
  28. 7.5.3 Kelun Biotech Radionuclide Drug Conjugate(RDC) Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Kelun Biotech Radionuclide Drug Conjugate(RDC) Product Portfolio
  30. 7.5.5 Kelun Biotech Recent Developments
  31. 7.6 Hengrui
  32. 7.6.1 Hengrui Company Information
  33. 7.6.2 Hengrui Business Overview
  34. 7.6.3 Hengrui Radionuclide Drug Conjugate(RDC) Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Hengrui Radionuclide Drug Conjugate(RDC) Product Portfolio
  36. 7.6.5 Hengrui Recent Developments
  37. 7.7 Fulian Pharmaceuticals
  38. 7.7.1 Fulian Pharmaceuticals Company Information
  39. 7.7.2 Fulian Pharmaceuticals Business Overview
  40. 7.7.3 Fulian Pharmaceuticals Radionuclide Drug Conjugate(RDC) Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Fulian Pharmaceuticals Radionuclide Drug Conjugate(RDC) Product Portfolio
  42. 7.7.5 Fulian Pharmaceuticals Recent Developments
  43. 7.8 Dongcheng Pharmaceuticals
  44. 7.8.1 Dongcheng Pharmaceuticals Company Information
  45. 7.8.2 Dongcheng Pharmaceuticals Business Overview
  46. 7.8.3 Dongcheng Pharmaceuticals Radionuclide Drug Conjugate(RDC) Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Dongcheng Pharmaceuticals Radionuclide Drug Conjugate(RDC) Product Portfolio
  48. 7.8.5 Dongcheng Pharmaceuticals Recent Developments
  49. 7.9 Bayer
  50. 7.9.1 Bayer Company Information
  51. 7.9.2 Bayer Business Overview
  52. 7.9.3 Bayer Radionuclide Drug Conjugate(RDC) Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Bayer Radionuclide Drug Conjugate(RDC) Product Portfolio
  54. 7.9.5 Bayer Recent Developments
  55. 7.10 Telix Pharmaceuticals
  56. 7.10.1 Telix Pharmaceuticals Company Information
  57. 7.10.2 Telix Pharmaceuticals Business Overview
  58. 7.10.3 Telix Pharmaceuticals Radionuclide Drug Conjugate(RDC) Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Telix Pharmaceuticals Radionuclide Drug Conjugate(RDC) Product Portfolio
  60. 7.10.5 Telix Pharmaceuticals Recent Developments
  61. 7.11 Lantheus
  62. 7.11.1 Lantheus Company Information
  63. 7.11.2 Lantheus Business Overview
  64. 7.11.3 Lantheus Radionuclide Drug Conjugate(RDC) Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Lantheus Radionuclide Drug Conjugate(RDC) Product Portfolio
  66. 7.11.5 Lantheus Recent Developments
  67. 7.12 Curium
  68. 7.12.1 Curium Company Information
  69. 7.12.2 Curium Business Overview
  70. 7.12.3 Curium Radionuclide Drug Conjugate(RDC) Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Curium Radionuclide Drug Conjugate(RDC) Product Portfolio
  72. 7.12.5 Curium Recent Developments
8 North America
  1. 8.1 North America Radionuclide Drug Conjugate(RDC) Revenue (2021-2032)
  2. 8.2 North America Radionuclide Drug Conjugate(RDC) Revenue by Type (2021-2032)
  3. 8.2.1 North America Radionuclide Drug Conjugate(RDC) Revenue by Type (2021-2026)
  4. 8.2.2 North America Radionuclide Drug Conjugate(RDC) Revenue by Type (2027-2032)
  5. 8.3 North America Radionuclide Drug Conjugate(RDC) Revenue Share by Type (2021-2032)
  6. 8.4 North America Radionuclide Drug Conjugate(RDC) Revenue by Application (2021-2032)
  7. 8.4.1 North America Radionuclide Drug Conjugate(RDC) Revenue by Application (2021-2026)
  8. 8.4.2 North America Radionuclide Drug Conjugate(RDC) Revenue by Application (2027-2032)
  9. 8.5 North America Radionuclide Drug Conjugate(RDC) Revenue Share by Application (2021-2032)
  10. 8.6 North America Radionuclide Drug Conjugate(RDC) Revenue by Country
  11. 8.6.1 North America Radionuclide Drug Conjugate(RDC) Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Radionuclide Drug Conjugate(RDC) Revenue by Country (2021-2026)
  13. 8.6.3 North America Radionuclide Drug Conjugate(RDC) Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Radionuclide Drug Conjugate(RDC) Revenue (2021-2032)
  2. 9.2 Europe Radionuclide Drug Conjugate(RDC) Revenue by Type (2021-2032)
  3. 9.2.1 Europe Radionuclide Drug Conjugate(RDC) Revenue by Type (2021-2026)
  4. 9.2.2 Europe Radionuclide Drug Conjugate(RDC) Revenue by Type (2027-2032)
  5. 9.3 Europe Radionuclide Drug Conjugate(RDC) Revenue Share by Type (2021-2032)
  6. 9.4 Europe Radionuclide Drug Conjugate(RDC) Revenue by Application (2021-2032)
  7. 9.4.1 Europe Radionuclide Drug Conjugate(RDC) Revenue by Application (2021-2026)
  8. 9.4.2 Europe Radionuclide Drug Conjugate(RDC) Revenue by Application (2027-2032)
  9. 9.5 Europe Radionuclide Drug Conjugate(RDC) Revenue Share by Application (2021-2032)
  10. 9.6 Europe Radionuclide Drug Conjugate(RDC) Revenue by Country
  11. 9.6.1 Europe Radionuclide Drug Conjugate(RDC) Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Radionuclide Drug Conjugate(RDC) Revenue by Country (2021-2026)
  13. 9.6.3 Europe Radionuclide Drug Conjugate(RDC) Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Radionuclide Drug Conjugate(RDC) Revenue (2021-2032)
  2. 10.2 China Radionuclide Drug Conjugate(RDC) Revenue by Type (2021-2032)
  3. 10.2.1 China Radionuclide Drug Conjugate(RDC) Revenue by Type (2021-2026)
  4. 10.2.2 China Radionuclide Drug Conjugate(RDC) Revenue by Type (2027-2032)
  5. 10.3 China Radionuclide Drug Conjugate(RDC) Revenue Share by Type (2021-2032)
  6. 10.4 China Radionuclide Drug Conjugate(RDC) Revenue by Application (2021-2032)
  7. 10.4.1 China Radionuclide Drug Conjugate(RDC) Revenue by Application (2021-2026)
  8. 10.4.2 China Radionuclide Drug Conjugate(RDC) Revenue by Application (2027-2032)
  9. 10.5 China Radionuclide Drug Conjugate(RDC) Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Radionuclide Drug Conjugate(RDC) Revenue (2021-2032)
  2. 11.2 Asia Radionuclide Drug Conjugate(RDC) Revenue by Type (2021-2032)
  3. 11.2.1 Asia Radionuclide Drug Conjugate(RDC) Revenue by Type (2021-2026)
  4. 11.2.2 Asia Radionuclide Drug Conjugate(RDC) Revenue by Type (2027-2032)
  5. 11.3 Asia Radionuclide Drug Conjugate(RDC) Revenue Share by Type (2021-2032)
  6. 11.4 Asia Radionuclide Drug Conjugate(RDC) Revenue by Application (2021-2032)
  7. 11.4.1 Asia Radionuclide Drug Conjugate(RDC) Revenue by Application (2021-2026)
  8. 11.4.2 Asia Radionuclide Drug Conjugate(RDC) Revenue by Application (2027-2032)
  9. 11.5 Asia Radionuclide Drug Conjugate(RDC) Revenue Share by Application (2021-2032)
  10. 11.6 Asia Radionuclide Drug Conjugate(RDC) Revenue by Country
  11. 11.6.1 Asia Radionuclide Drug Conjugate(RDC) Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Radionuclide Drug Conjugate(RDC) Revenue by Country (2021-2026)
  13. 11.6.3 Asia Radionuclide Drug Conjugate(RDC) Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Radionuclide Drug Conjugate(RDC) Revenue (2021-2032)
  2. 12.2 SAMEA Radionuclide Drug Conjugate(RDC) Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Radionuclide Drug Conjugate(RDC) Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Radionuclide Drug Conjugate(RDC) Revenue by Type (2027-2032)
  5. 12.3 SAMEA Radionuclide Drug Conjugate(RDC) Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Radionuclide Drug Conjugate(RDC) Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Radionuclide Drug Conjugate(RDC) Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Radionuclide Drug Conjugate(RDC) Revenue by Application (2027-2032)
  9. 12.5 SAMEA Radionuclide Drug Conjugate(RDC) Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Radionuclide Drug Conjugate(RDC) Revenue by Country
  11. 12.6.1 SAMEA Radionuclide Drug Conjugate(RDC) Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Radionuclide Drug Conjugate(RDC) Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Radionuclide Drug Conjugate(RDC) Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst